VISEN Pharmaceuticals

Executive Summary

VISEN Pharmaceuticals is a Shanghai-based biopharmaceutical company specializing in endocrine and rare diseases, leveraging Ascendis Pharma's proprietary TransCon technology to develop long-acting prodrug therapies for Greater China. Founded in 2018, the company has raised $150 million and is focused on commercializing treatments for growth hormone deficiency, hypoparathyroidism, and achondroplasia. By securing exclusive licenses to TransCon-based assets, VISEN aims to address significant unmet medical needs in China, where endocrine disorders represent a growing market. The company's lead programs include TransCon hGH (for growth hormone deficiency) and palopegteriparatide (for hypoparathyroidism), both of which have shown positive clinical data globally. With a commercial-stage designation and a net of licensed products, VISEN is positioned to capture market share through local manufacturing and regulatory expertise. However, its success is contingent on NMPA approvals and competition from other developers in the region. The company's future growth hinges on timely regulatory milestones and expansion into adjacent indications.

Upcoming Catalysts (preview)

• Q3 2026NMPA Decision on TransCon hGH for Pediatric Growth Hormone Deficiency75% success
• Q4 2026Phase 3 Results for Palopegteriparatide in Hypoparathyroidism China Trial60% success
• TBDPotential Strategic Partnership or Licensing Expansion for Achondroplasia Program40% success